

## **Azedra Policy**

### **Purpose**

To describe the CVS Radiation Oncology External Policy for Azedra.

### **Scope**

The scope of this document applies to CVS Health clients who have signed up for the CVS Radiation Oncology program under CVS Health Solutions. This document includes the external policy details for the Azedra policy.

### **Policy**

CVS Health considers Azedra medically necessary for the treatment of an individual aged 12 years and older with iobenguane scan positivity who has inoperable locally advanced or metastatic pheochromocytoma or paraganglioma requiring systemic treatment.

## References

The Azedra policy is based on the following references:

1. National Comprehensive Cancer Network® (NCCN® ) Guidelines® Version 2.2022 – December 21, 2022. Neuroendocrine and Adrenal Tumors. [https://www.nccn.org/professionals/physician\\_gls/pdf/neuroendocrine.pdf](https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf). Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) for Neuroendocrine and Adrenal Tumors Version 2.2022. © 2022 National Comprehensive Cancer Network® (NCCN® ). All rights reserved. NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines® , go online to NCCN.org.
2. Azedra. Prescribing information. Progenics Pharmaceuticals, Inc; 2018 (revised 7/2018). [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2018/209607s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209607s000lbl.pdf)
3. van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP. (131)I-MIBG therapy for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. *Clin Endocrinol (Oxf)*. 2014;80(4):487-501. doi:10.1111/cen.12341